ArticleEye (London, England)2013
United Kingdom National Ophthalmology Database Study: Diabetic Retinopathy; Report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services.
Article in Eye (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.The Journal of clinical endocrinology and metabolism · 2019Guideline
- Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease.Eye (London, England) · 2017Guideline
- Magnitude, patterns, and determinant factors of diabetic macular edema among people with diabetes at Debre Markos Referral Hospital, Northwest Ethiopia, 2025: a hospital-based cross-sectional study.International ophthalmology · 2026Article
- Predictive factors for visual acuity in diabetic macular oedema: lessons for clinical practice learned from deferring intravitreal injections under the COVID-19 pandemic.Eye (London, England) · 2026Article
- Diabetic Retinopathy Screening: Predictors and Barriers Among Patients With Diabetes Mellitus in South-West Nigeria.Cureus · 2026Article
- Investigating the barriers to implementation of new technology in primary eye care: a qualitative study.BMJ open ophthalmology · 2025Article
- Article
- Intravitreal injections: past trends and future projections within a UK tertiary hospital.Eye (London, England) · 2022Article
- Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire.Acta ophthalmologica · 2022Observational
- Synthesis, Antioxidant, and Antidiabetic Activities of Ketone Derivatives of Succinimide.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Reduced Level of Tear Antimicrobial and Immunomodulatory Proteins as a Possible Reason for Higher Ocular Infections in Diabetic Patients.Pathogens (Basel, Switzerland) · 2021Article
- Article
- Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study.Health technology assessment (Winchester, England) · 2021Article
- Implementation of Lean healthcare methodology in designing an Intravitreal Injection Center: first Italian experience.International ophthalmology · 2020Article
- Towards implementation of AI in New Zealand national diabetic screening program: Cloud-based, robust, and bespoke.PloS one · 2020Article
- Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Effect of Intravitreal Anti-Vascular Growth Factor Agents With or Without Macular Photocoagulation on Diabetic Macular Edema: A Systematic Review and Meta-Analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Article
- Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy (EMERALD).BMJ open · 2019Article
- Profile of a population-based diabetic macular oedema study: the Liverpool Eye and Diabetes Study (Sydney).BMJ open · 2019Observational
- Role of a mydriasis-free, full-field flicker ERG device in the detection of diabetic retinopathy.Documenta ophthalmologica. Advances in ophthalmology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
aimsTo report estimates of the prevalence of diabetic retinopathy (DR) and maculopathy grades for a large cohort of patients managed by the UK hospital eye service (HES).
methodsAnonymised data were extracted from 30 UK NHS hospital trusts using a single ophthalmic electronic medical record (EMR) for the period from April 2000 to November 2010 to create the National Ophthalmology Database (NOD). From 2007, the EMR facilitated capture of a nationally agreed-upon standardised data set (DR Structured Assessment) relating to the presence or absence of clinical signs of DR and maculopathy. An algorithm in the software automatically calculated the Early Treatment of Diabetic Retinopathy Study grades of retinopathy and maculopathy.
resultsBetween 2007 and 2010, 307,538 patients had data on the NOD, with 76,127 (24.8%) patients having been recorded as having diabetes. The proportion of patients with diabetes who had a structured assessment increased from 50.7% (2007) to 86.8% (2010). In each NHS year, 12.6-20.6% of eyes with structured assessments had no DR; 59.6-67.3% had non-proliferative DR; and 18.3-20.9% had active or regressed proliferative DR. Clinically significant macular oedema was present in 15.8-18.1% of eyes, and in 8.7-10.0% of eyes, this involved the central macula.
conclusionThis study provides contemporary estimates of the prevalence of retinopathy and maculopathy grades in a large cohort of patients with diabetes managed by the UK HES. Centre-involving diabetic macular oedema, potentially amenable to anti-VEGF therapy, is present in the eyes of almost 10% of these patients. This information is useful for clinicians, health-care economists, and commissioners involved in planning and delivering diabetic eye services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.